



Contact: Jennifer Cook Williams
Investor Relations
ImmunoCellular Therapeutics, Ltd.
(360) 668-3701
ir@imuc.com

ImmunoCellular Therapeutics to Present at Bio International Convention Additional Presentation to be Made at Stem Cell Research Meeting

LOS ANGELES, CA – June 11, 2008 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, today announced that Manish Singh, Ph.D., president and chief executive officer, will present next week at the BIO Business Forum during the 2008 BIO International Convention to be held in San Diego, California from June 17-20. Dr. Singh will present at 10:45 am PDT on Thursday, June 19th, and will provide the audience with an overview of IMUC's monoclonal antibody platform and preclinical-stage programs targeting multiple cancers. The lead compound, ICT-109, is a preclinical monoclonal antibody targeting small cell lung cancer and pancreatic cancer. The company is also developing a diagnostic test to potentially screen patients with these tumor markers who are most likely to benefit from this therapy.

Additionally, John Yu, M.D., chief scientific officer, scientific founder and chairman of the board of IMUC, will present data relating to the company's cancer stem cell vaccine program at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Philadelphia, PA. The presentation, which will take place on Friday, June 13th, includes preclinical data which support the company's premise of its cancer stem cell program that demonstrate that cancer stem cells are the most virulent and hierarchically most important cell of a brain tumor and therefore the cell that should be targeted with an immunotherapy such as IMUC's ICT-111-a cancer stem cell vaccine that IMUC is targeting to enter a Phase I clinical trial for glioblastoma in the fourth quarter of 2008.

"We are pleased to have an opportunity to present at these important conferences. At the BIO Meeting, I look forward to providing an update on our preclinical-stage antibodies which were discovered by differential immunization. This technology allows one to find novel antibodies against epitopes on cancer cells that are otherwise extremely difficult to identify. We are excited about the promising preclinical data demonstrating high specificity of these antibodies to target certain cancers and our in vivo targeting data demonstrating a potential ability to hone these to tumor sites," stated Dr. Singh. "We are also excited about the opportunity to present data at the ISSCR Annual Meeting enabling us to further discuss encouraging preclinical data supporting our cancer stem cell vaccine program, which we expect to advance into human clinical trials for glioblastoma in the fourth quarter of this year."

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based development stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate-a dendritic

cell-based vaccine for treating brain tumors-is currently being evaluated in a Phase I clinical trial. Additionally, the company is developing a therapeutic vaccine targeting cancer stem cells for multiple cancer indications and will also begin evaluating its newly acquired monoclonal antibody-related technology for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need to confirm pre-clinical monoclonal antibody data characterizing distinct antigens between cancers; the risk that monoclonal antibody therapeutics based on disparities in CEA sugar patterns may not prove to be safer or more efficacious than other therapeutics; the risks associated with obtaining FDA clearance to initiate the Phase I trial for the stem cell cancer vaccine in a timely manner or at all; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risks associated with obtaining and maintaining patent protection for vaccine and antibody product candidates and the lack of patent coverage for the differential immunization platform discovery technology; and the risk of the ability to retain and recruit senior management personnel. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###